Neumora Therapeutics, Inc. (NMRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $80.59M
Last updated: Nov 17, 2026 at 11:03 AM ET
Neumora Therapeutics, Inc. (NMRA) Stock Forecast
Analysts expect Neumora Therapeutics (NMRA) to earn -$0.87 per share in the fiscal year ending Dec 31, 2026. Of 9 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.22, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 78% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 22.2% |
| Buy | 5 | 55.6% |
| Hold | 1 | 11.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 11.1% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.87
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.61
- EPS consensus
- Next report
- Nov 19, 2026
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.87 | -$0.94 to -$0.65 | 7 |
| Dec 31, 2027 | -$0.61 | -$0.88 to -$0.33 | 7 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.18 | -$0.20 to -$0.14 | 10 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.91.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.87 | -$0.86 | -$0.87 | -$0.87 | -$0.91 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.61 | -$0.65 | -$0.67 | -$0.67 | -$0.73 | N/A |
Frequently Asked Questions About NMRA
What is the NMRA stock forecast?
Consensus analyst estimates put Neumora Therapeutics's EPS at -$0.87 for the fiscal year ending Dec 31, 2026. The consensus rating from 9 analysts is Buy.
How do analysts rate NMRA stock?
Of 9 analysts covering Neumora Therapeutics, 2 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NMRA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.87, with estimates from -$0.94 to -$0.65 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.61, with estimates from -$0.88 to -$0.33 from 7 analysts.
How many analysts cover NMRA?
9 analysts rate Neumora Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NMRA pages: Overview, Earnings, Forecast, Financials, Competitors